Thyrocare Technologies Ltd Stock Price Today (NSE: THYROCARE)
Fundamental Score
Thyrocare Technologies Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Thyrocare Technologies Ltd share price today is ₹0.00, up +0.00% on NSE/BSE as of 17 July 2026. Thyrocare Technologies Ltd (THYROCARE) is a Mid-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹8.42K (Cr). The 52-week high for THYROCARE share price is ₹N/A and the 52-week low is ₹342.55. At a P/E ratio of 52.36x, THYROCARE is currently trading above its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 28.40% and a debt-to-equity ratio of 0.09.
Thyrocare Technologies Ltd Share Price Chart — NSE/BSE Historical Performance
Thyrocare Technologies Ltd share price chart: -100.00% return over the past month. 52-week high ₹N/A, 52-week low ₹342.55.
Thyrocare Technologies Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹NaN | ₹NaN | ₹NaN | ₹NaN | 3.36L (Cr) | |
| ₹506.05 | ₹544.40 | ₹506.05 | ₹540.45 | 7.51L (Cr) | |
| ₹512.00 | ₹519.95 | ₹505.50 | ₹510.15 | 4.54L (Cr) | |
| ₹543.10 | ₹543.90 | ₹511.65 | ₹515.70 | 4.21L (Cr) | |
| ₹526.00 | ₹539.50 | ₹523.10 | ₹535.55 | 1.86L (Cr) | |
| ₹529.85 | ₹539.25 | ₹511.75 | ₹521.70 | 3.44L (Cr) | |
| ₹545.20 | ₹548.15 | ₹523.10 | ₹532.00 | 2.71L (Cr) | |
| ₹554.05 | ₹557.95 | ₹537.40 | ₹545.20 | 2.38L (Cr) | |
| ₹557.20 | ₹565.00 | ₹551.75 | ₹555.60 | 2.31L (Cr) | |
| ₹544.00 | ₹558.45 | ₹540.95 | ₹557.20 | 1.84L (Cr) |
Thyrocare Technologies Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹554.90 | ₹NaN | ₹NaN | ₹NaN | NaN% | |
| ₹528.75 | ₹574.90 | ₹488.64 | ₹549.30 | +3.89% | |
| ₹400.65 | ₹526.00 | ₹399.75 | ₹506.30 | +26.37% | |
| ₹359.55 | ₹418.00 | ₹352.90 | ₹400.30 | +11.33% | |
| ₹375.20 | ₹392.60 | ₹342.55 | ₹349.55 | -6.84% | |
| ₹404.95 | ₹425.05 | ₹376.50 | ₹393.65 | -2.79% | |
| ₹445.00 | ₹508.00 | ₹397.50 | ₹420.00 | -5.62% | |
| ₹489.00 | ₹492.00 | ₹408.10 | ₹445.70 | -8.85% | |
| ₹1405.00 | ₹1610.00 | ₹482.00 | ₹495.70 | -64.72% | |
| ₹1159.90 | ₹1474.00 | ₹1130.00 | ₹1397.30 | +20.47% | |
| ₹1255.00 | ₹1383.60 | ₹1091.20 | ₹1160.60 | -7.52% | |
| ₹1331.00 | ₹1435.00 | ₹1247.30 | ₹1265.30 | -4.94% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Overvalued diagnostic play with promoter pledging issues; chasing momentum is a dangerous game.
WHAT'S HAPPENING NOW
Based on the provided brief, Thyrocare Technologies is contesting a Crore tax demand. No major catalysts found after live search.
CORE STORY
Thyrocare is a bet on the growth of diagnostic testing in India, but faces headwinds from competition and pricing pressure. Market likely pricing in a rebound in profitability after a period of slower growth.
- YoY Profit Growth of 79.94%
- 6M price momentum of 45.48%
- FII interest increasing (Δ 1.62%)
- Stronger than expected earnings
- Significant order wins
- Reduction in promoter pledging
- Expensive valuation (P/E 60.48x vs Industry P/E 39.28x)
- High promoter pledge (85.84%)
- Negative Profit CAGR 5Y (-0.64%)
FII increasing stake (Δ 1.62%), DII decreasing stake (Δ -1.07%).
Healthcare sector in India is growing, but faces increasing competition and pricing pressure.
Profit converting to cash, Free Cash Flow 5Y: ₹532.83 Cr
Next 3-6 months depend on maintaining current profit growth. Key risk is a slowdown in growth or increased competition.
Primary Thesis Risk
Sustained earnings growth is not guaranteed, and valuation is already stretched.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Thyrocare Technologies Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Thyrocare Technologies Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of THYROCARE across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (28.40%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (35.38%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (29.70%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (117.14%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (19.66%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.09)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (53.98x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹637.23 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (60.92%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 26.36%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 52.36x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Share Pledging Risk (100.00%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Thyrocare Technologies Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Thyrocare Technologies Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Thyrocare Technologies LtdThyrocare Techn...Selected✓ THYROCARE • 539871 | 46.7/100 | ₹0.00₹0 | ₹8420.27₹8420.27 | 52.36Average 52.4 Average | 28.40%Excellent 28.40% Excellent | 35.38%Excellent 35.38% Excellent | 0.09Excellent 0.1 Excellent | 8.37%Good 8.37% Good | 10.88%Good 10.88% Good | 1.76% |
Dr Lal PathLabs LtdDr Lal PathLabs... LALPATHLAB • 539524 | 57.7/100 | ₹1723.30₹1723 | ₹28908.91₹28908.91 | 55.39Average 55.4 Average | 22.30%Excellent 22.30% Excellent | 28.00%Excellent 28.00% Excellent | 0.08Excellent 0.1 Excellent | 12.33%Good 12.33% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LtdVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1261.40₹1261 | ₹14307.85₹14307.85 | 82.71Average 82.7 Average | 19.74%Good 19.74% Good | 21.29%Excellent 21.29% Excellent | 0.44Excellent 0.4 Excellent | 15.47%Excellent 15.47% Excellent | 16.66%Excellent 16.66% Excellent | 0.14% |
Metropolis Healthcare LtdMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹571.65₹572 | ₹11858.49₹11858.49 | 60.38Average 60.4 Average | 13.81%Average 13.81% Average | 17.77%Good 17.77% Good | 0.15Excellent 0.1 Excellent | 1.46%Average 1.46% Average | 10.52%Good 10.52% Good | 0.35% |
Krsnaa Diagnostics LtdKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹549.05₹549 | ₹1777.47₹1777.47 | 17.31Average 17.3 Average | 10.89%Average 10.89% Average | 12.70%Average 12.70% Average | 0.54Good 0.5 Good | -11.13%Poor -11.13% Poor | 11.75%Good 11.75% Good | 0.50% |
3B Blackbio Diagnostics Ltd3B Blackbio Dia... 3BBLACKBIO • 532067 | 60.3/100 | ₹1272.00₹1272 | ₹1079.13₹1079.13 | 18.42Average 18.4 Average | 19.77%Good 19.77% Good | 25.48%Excellent 25.48% Excellent | 0.01Excellent 0.0 Excellent | -12.44%Poor -12.44% Poor | -8.95%Poor -8.95% Poor | 0.31% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹245.70₹246 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Aspira Pathlab & Diagnostics LimitedAspira Pathlab ... ASPIRA • 540788 | 11.9/100 | ₹86.00₹86 | ₹88.52₹88.52 | 1770.34Average 1770.3 Average | 0.51%Poor 0.51% Poor | 2.84%Poor 2.84% Poor | 0.27Excellent 0.3 Excellent | -48.50%Poor -48.50% Poor | 10.43%Good 10.43% Good | 0.00% |
Choksi Imaging LtdChoksi Imaging ... CHOKSI • 526546 | 36.3/100 | ₹174.55₹175 | ₹81.49₹81.49 | 54.33Average 54.3 Average | 6.10%Poor 6.10% Poor | 9.64%Poor 9.64% Poor | 1.20Average 1.2 Average | 20.80%Excellent 20.80% Excellent | 12.36%Good 12.36% Good | 0.00% |
Medinova Diagnostic Services IncMedinova Diagno... MEDINOV • 526301 | 49/100 | ₹43.45₹43 | ₹43.37₹43.37 | 20.17Average 20.2 Average | — — | 108.87%Excellent 108.87% Excellent | — — | 56.49%Excellent 56.49% Excellent | 5.66%Good 5.66% Good | 0.00% |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr Lal PathLabs Ltd share price28908.91 Cr
- Vijaya Diagnostic Centre Ltd share price14307.85 Cr
- Metropolis Healthcare Ltd share price11858.49 Cr
- Krsnaa Diagnostics Ltd share price1777.47 Cr
- 3B Blackbio Diagnostics Ltd share price1079.13 Cr
Thyrocare Technologies Ltd PE Ratio History
Historical price-to-earnings ratio for THYROCARE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹17.23 | ₹445.70 | 25.9x |
| FY 2024 | ₹13.34 | ₹911.80 | 68.3x |
| FY 2023 | ₹12.14 | ₹643.55 | 53x |
| FY 2022 | ₹33.25 | ₹618.65 | 18.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Thyrocare Technologies Ltd Dividend History
Annual cash dividends paid by THYROCARE — dividend yield 1.76%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹95.31 Cr |
| FY 2024 | ₹95.27 Cr |
| FY 2023 | ₹79.35 Cr |
| FY 2022 | ₹79.31 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Thyrocare Technologies Ltd Quarterly Performance
Latest quarterly metrics for THYROCARE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.66%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
117.14%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.88%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
8.37%
Compounded annual net profit growth over 5 years
Thyrocare Technologies Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for THYROCARE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Thyrocare Technologies Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Thyrocare Technologies Ltd (THYROCARE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Thyrocare Technologies Ltd
About THYROCARE (Thyrocare Technologies Ltd)
Thyrocare Technologies Ltd is a pioneering force in the Indian diagnostic industry, revolutionizing healthcare accessibility with its innovative and cost-effective testing solution...s. The company operates on a centralized processing laboratory model, enabling it to offer a comprehensive range of tests at affordable prices, making quality healthcare accessible to a wider population. Thyrocare focuses on preventive care, empowering individuals to proactively monitor their health and well-being through early detection and timely intervention. With a strong emphasis on automation and technology, Thyrocare has established itself as a reliable and efficient provider of diagnostic services, consistently delivering accurate and timely results. At the heart of Thyrocare's operations lies its Diagnostic Testing Services division, where the company meticulously processes a vast array of samples, ensuring precision and reliability in every test result. This segment is the backbone of Thyrocare, encompassing the sale of essential consumables required for sample collection, as well as strategic promotional activities designed to increase awareness and demand for pathology testing. Further expanding its diagnostic capabilities, Thyrocare's Imaging Services segment plays a crucial role in providing advanced imaging solutions. This division focuses on the sale of radio-pharmaceuticals and specialized consumables essential for accurate image reporting, contributing to comprehensive patient diagnosis and treatment planning. Beyond diagnostic testing and imaging, Thyrocare demonstrates its commitment to innovation through its "Others" segment. This division is dedicated to the sale of cutting-edge testing equipment and related consumables, supporting laboratories and healthcare facilities across India. By offering these essential resources, Thyrocare empowers healthcare providers to enhance their own diagnostic capabilities, ultimately contributing to the overall improvement of healthcare standards. Through its diverse offerings and unwavering focus on quality and affordability, Thyrocare Technologies Ltd continues to play a vital role in transforming the Indian healthcare landscape.
Company Details
Key Leadership
Corporate Events
Latest News
THYROCARE Share Price: Frequently Asked Questions
What is the current share price of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd (THYROCARE) trades at ₹N/A on NSE and BSE. Market cap ₹8.42K (Cr). Educational data only.
What is the P/E ratio of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd has a P/E of 52.36x vs industry average 42.23x.
What is the Bull Run score for Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd has a Bull Run score of 46.7/100 based on 25+ financial parameters.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd has a dividend yield of 1.76%. Past dividends don't guarantee future payments.
What is the ROE of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd has ROE of 28.40%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd has debt-to-equity of 0.09.
Is Thyrocare Technologies Ltd a good investment?
Bull Run gives Thyrocare Technologies Ltd a score of 46.7/100. This is not investment advice — consult a SEBI-registered advisor.